Ventricular arrhythmias. Re-entry ventricular arrhythmia
Conditions
Interventions
Intervention 1: Intervention group: Intervention group:Colchicine 1 mg tablets, Mofid Pharmaceuticals, once a day for three months (67 people). Intervention 2: Control group: Control group: Placebo ta
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age more than 18 years Having an implantable cardioverter-defibrillator for more than 3 months before starting participation in the clinical trial Obtaining the patient's informed consent
Exclusion criteria
Exclusion criteria: Taking the drug Colchicine before Pregnancy or suspected pregnancy Active inflammation or infection Suffering from autoimmune diseases and malignancies Taking class I and III antiarrhythmic drugs Performing major surgeries Treatment with corticosteroids or other immunosuppressive drugs Moderate to severe kidney dysfunction (GFR < 30 ml/min/1.73m2) Significant impairment of liver function (Child-Pugh class B or C) Concomitant use of strong Cyp3A4 inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of ventricular arrhythmias. Timepoint: The beginning of the study and 3 months later. Method of measurement: Examining the data obtained from the implantable cardiac defibrillator device. | — |
Secondary
| Measure | Time frame |
|---|---|
| CRP level. Timepoint: Before the intervention and after 3 months. Method of measurement: Biochemistry test of the patient's blood sample.;Blood pressure. Timepoint: Before the intervention and after 3 months. Method of measurement: sphygmomanometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Hooshang Mohammadpour
Mashhad University of Medical Sciences
Outcome results
None listed